...
首页> 外文期刊>Drug discovery today >From clinical proof-of-concept to commercialization of CAR T cells
【24h】

From clinical proof-of-concept to commercialization of CAR T cells

机译:从临床概念验证到汽车T细胞的商业化

获取原文
获取原文并翻译 | 示例
           

摘要

The development of CAR T cells currently represents an exciting opportunity to convert the already published clinical successes observed in clinical trials into commercially available efficient therapies. However, the path toward successful commercialization is still hindered by many hurdles. Here, we review such issues as: the need for structured collaborations between hospital collection and clinical facilities and industry manufacturing facilities to streamline the supply chain; necessity for uniform and efficient medical procedures to cope with severe toxicities associated with CART cells; and absolute need to define an economical and sustainable model for manufacturers and payers. The fast pace at which the field is evolving requires careful assessments for the benefit of patients.
机译:汽车T细胞的发展目前代表了将在临床试验中观察到的已经发表的临床成功转化为商业上可用的有效疗法的令人兴奋的机会。 然而,成功商业化的道路仍然受到许多障碍的阻碍。 在这里,我们审查了以下问题:需要在医院收集和临床设施和行业制造工具之间进行结构化合作,以简化供应链; 统一和有效的医疗程序的必要性,以应对与购物车相关的严重毒性; 绝对需要为制造商和付款人定义一个经济和可持续的模式。 该领域正在发展的快速节奏需要仔细评估患者的利益。

著录项

  • 来源
    《Drug discovery today》 |2018年第4期|共5页
  • 作者单位

    Aix Marseille Univ Inst Paoli Calmettes AP HM CBT INSERM 1409 Marseille France;

    Aix Marseille Univ Inst Paoli Calmettes AP HM CBT INSERM 1409 Marseille France;

    Aix Marseille Univ Inst Paoli Calmettes AP HM CBT INSERM 1409 Marseille France;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 药学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号